- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
11 result(s) found for: Pervasive Developmental Disorder.
Displaying page 1 of 1.
EudraCT Number: 2016-002875-81 | Sponsor Protocol Number: NL58621.041.16 | Start Date*: 2016-10-19 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UMC Utrecht | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Bumetanide for the Autism Spectrum Clinical Effectiveness Trial | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Epilepsy | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005346-37 | Sponsor Protocol Number: F1D-MC-HGMR | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Maintenance of Effect Study of Olanzapine in the Treatment of Disruptive Behavioral Symptoms in Children and Adolescents with Pervasive Developmental ... | |||||||||||||
Medical condition: children and adolescents with disruptive behavioral symptoms associated with Pervasive Developmental Disorders (PDD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001630-33 | Sponsor Protocol Number: MEM-MD-69 | Start Date*: 2012-11-14 | |||||||||||||||||||||
Sponsor Name:Forest Research Institute, Inc | |||||||||||||||||||||||
Full Title: An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients with Autism, Asperger’s Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) | |||||||||||||||||||||||
Medical condition: Autism or Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated with Memantine | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) FR (Ongoing) IS (Prematurely Ended) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-001568-31 | Sponsor Protocol Number: MEM-MD-68 | Start Date*: 2012-11-14 | |||||||||||||||||||||
Sponsor Name:Forest Research Institute, Inc | |||||||||||||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder ... | |||||||||||||||||||||||
Medical condition: Autism or Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated with Memantine | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) FR (Ongoing) IT (Completed) IS (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-001616-33 | Sponsor Protocol Number: MEM-MD-91 | Start Date*: 2012-11-14 | |||||||||||||||||||||
Sponsor Name:Forest Research Institute, Inc. | |||||||||||||||||||||||
Full Title: An Open-Label Study Of The Safety And Tolerability Of Memantine In Pediatric Patients With Autism, Asperger’s Disorder, Or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) | |||||||||||||||||||||||
Medical condition: Autism or Asperger’s Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) IS (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004378-32 | Sponsor Protocol Number: WN39434 | Start Date*: 2018-09-26 | |||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||
Full Title: A phase III, randomized, double-blind, placebo-controlled, efficacy, and safety study of Balovaptan in adults with Autism Spectrum Disorder with a 2 year open-label extension. | |||||||||||||||||||||||
Medical condition: Autism Spectrum Disorder | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) FR (Completed) IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-001909-25 | Sponsor Protocol Number: | Start Date*: Information not available in EudraCT |
Sponsor Name: | ||
Full Title: Effekter av behandling med atomoxetine ved komorbid ADHD hos pasienter med Pervasive Developmental Disorders (Effects of treatment with atomoxetine in children with Pervasive Developmental Disorder... | ||
Medical condition: Open treatment with atomoxetine for 10 weeks: •Week 1: 0,5 mg/kg/day in 1 or 2 doses. •Week 2 – 6: 1,2 mg/kg/day i 1 or 2 doses. •Week 6 – 8: Significant improvements: Continue on 1,2 mg/kg/day in ... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001523-39 | Sponsor Protocol Number: D1050300 | Start Date*: 2013-11-08 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A PHASE 1 OPEN-LABEL, MULTICENTER, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LURASIDONE IN SUBJECTS 6 TO 17 YEARS OLD WITH SCHIZOPHRENIA SPE... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006444-21 | Sponsor Protocol Number: EC07/90076 | Start Date*: 2009-02-13 | |||||||||||
Sponsor Name:Fundación para la Investigación Biomédica Hospital Gregorio Marañón | |||||||||||||
Full Title: EFFECT OF 8-WEEK FATTY ACIDS OMEGA-3 TREATMENT ON OXIDATIVE METABOLISM IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMISED DOUBLE-BLIND CROSSOVER PLACEBO-CONTROLLED TRIAL. | |||||||||||||
Medical condition: autism spectrum disorders Trastornos del Espectro Autista | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001694-24 | Sponsor Protocol Number: D1050302 | Start Date*: 2014-03-11 | |||||||||||
Sponsor Name:SUNOVION PHARMACEUTICALS INC. | |||||||||||||
Full Title: A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN PEDIATRIC SUBJECTS WITH SCHIZOPHRENIA AND SUBJECTS WITH IRRIT... | |||||||||||||
Medical condition: SCHIZOPHRENIA AND IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Prematurely Ended) BG (Completed) Outside EU/EEA HU (Completed) GB (Completed) DE (Completed) PL (Completed) BE (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000304-16 | Sponsor Protocol Number: B4Z-UT-S017 | Start Date*: 2021-12-02 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder. | |||||||||||||
Medical condition: Attention-Deficit/Hyperactivity Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.